Castle Biosciences CEO Derek Maetzold Buys Company Shares

Castle Biosciences, Inc. (NasdaqGM: CSTL) saw insider activity as its President and CEO, Derek Maetzold, bought 550 shares at $2.39 each on June 15, 2026. This purchase amounted to $1,314.50. The transaction was not part of a pre-planned trading program.

Insider Buying and Selling at Castle Biosciences, Inc.

Derek Maetzold, the CEO of Castle Biosciences, actively traded shares on June 15, 2026. He purchased 550 shares at $2.39 each, totaling $1,314.50. On the same day, he sold 4,172 shares at $20.66 each as part of a planned transaction and sold 550 shares in a non-planned transaction. Earlier, on June 1, 2026, Maetzold bought 6,214 shares at $2.39 and sold 6,214 shares at no cost, along with another planned sale of 9,836 shares at $20.86.

Other Institutional Activity in Castle Biosciences

Institutional investors have shown varied interest in Castle Biosciences. BlackRock, Inc. reduced its stake by 122,300 shares, leaving it with 2,982,946 shares valued at about $73.2 million. On the other hand, RTW Investments, LP increased its position by 643,098 shares, holding 2,758,335 shares worth $67.7 million. Portolan Capital Management, LLC cut back significantly, reducing its holdings by 379,180 shares to 1,350,283 shares valued at $33.1 million. Meanwhile, Dimensional Fund Advisors LP decreased its position by 104,038 shares, now holding 1,039,761 shares worth approximately $25.5 million.

Castle Biosciences, Inc. Stock Down 38.9%

Shares of Castle Biosciences traded at $20.46, with a market capitalization of roughly $620.6 million. The company is not currently profitable, reflected in its negative forward P/E ratio. The stock's 52-week range spans from $14.59 to $44.28, with a 50-day moving average of $22.10 and a 200-day moving average of $28.74. Castle Biosciences has a healthy current ratio of 6.75 and a quick ratio of 6.26, indicating strong liquidity. The debt-to-equity ratio stands at 7.96.

Recent Earnings

In its recent earnings report, Castle Biosciences posted revenue of $339.9 million, though it experienced a decline with a revenue growth rate of -4.9%. The company reported a net margin of -3.78% and a return on equity of -2.85%. The next earnings announcement is expected on August 3, 2026.

Analysts Set New Price Targets

Analysts have consistently maintained a positive outlook on Castle Biosciences. On May 13, 2026, BTIG maintained its 'buy' rating with a price target of $40. Similarly, Baird reaffirmed a 'buy' rating with a $43 target on May 7, 2026. The consensus among eight analysts is a 'buy' recommendation, with a mean target price of $44.

About Castle Biosciences

Castle Biosciences, Inc. is a molecular diagnostics company based in Friendswood, Texas. It focuses on developing and selling tests that help diagnose and treat various dermatologic cancers, Barrett's esophagus, atopic dermatitis, and uveal melanoma. The company's products include DecisionDx-Melanoma, TissueCypher, and MyPath Melanoma, among others. Founded in 2007, Castle Biosciences serves primarily dermatology and gastroenterology markets and employs around 942 people.

Bottom Line

Derek Maetzold's recent share purchase in Castle Biosciences reflects ongoing insider interest in the company. Investors often track such insider activity for potential insights. However, it's important to remember that these trades are part of periodic filings and may not represent current positions. Castle Biosciences remains a focus for analysts, who continue to recommend the stock with a 'buy' rating.